CD38 and Miyoshi myopathy: Anti-CD38 mAbs elicit their action targeting CD38+ MM cells and inducing effector mechanisms such as ADCC (which relies mainly on natural killer [NK] cells), ADCP, and CDC [18,19,20,21].